Healthtech company PharmEasy seems to finally be able to hold its head above water. The unicorn, which has been struggling with slowing growth, debt burden, and steep valuation cuts by investors, had something to cheer about when it turned Ebitda (earnings before interest, taxes, depreciation and amortisation) profitable in April this year. For venture capital and private equity money backed startups the fund crunch that started in 2022 has
Business News›Prime›Pharma›PharmEasy has skipped the growth pill for profitability. This may lead to side effects
Under the lens
PharmEasy has skipped the growth pill for profitability. This may lead to side effects
Synopsis
PharmEasy has cut costs sharply to turn Ebitda positive. It hopes this will help in the next fund-raising round. But it has come at the cost of growth. How long will this trade-off be sustainable?
- FONT SIZEAbcSmallAbcMediumAbcLarge
ET
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Get Unlimited Access to The Economic Times
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
